Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
ConditionAtrial Fibrillation (AF)
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Luebeck
About this trial
To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.
Eligibility criteria
Qualifiers
Age 18-80 years
Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation
Body mass index ≥30 kg/m or body mass index ≥28 kg/m plus ≥1 weight-related comorbidity
No prior treatment with glucacon-like peptide-1 receptor agonists
Disqualifiers
Current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening
Current antiobesity medication use or use within the last 90 days prior to screening
A self-reported change in body weight of >5 kg within 30 days before screening
History of bariatric surgery
Trial design
Treatments tested in this trial
- Semaglutide (SEMA)
Treatment groups
240 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov